MRTX1133
MRTX1133 was the first potent chemical tool against KRAS G12D, and proved the mutation could be drugged even though it lacks the reactive handle G12C has.
Mirati (now BMS) non-covalent G12D inhibitor; striking regressions in pancreatic PDX models (Nature 2023). Poor oral bioavailability required intravenous dosing in the phase 1/2 trial; development pace slowed after the BMS acquisition, while covalent RAS(ON) competitors advanced.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"MRTX1133" OR ABSTRACT:"MRTX1133") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MRTX1133, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductElironrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- CompanyQuanta Therapeutics
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductZoldonrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- TrialRASolute 302
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.